Show simple item record

dc.contributor.authorChan, D.
dc.contributor.authorChen, Meifania
dc.contributor.authorOoi, E.
dc.contributor.authorWatts, G.
dc.date.accessioned2017-01-30T12:32:20Z
dc.date.available2017-01-30T12:32:20Z
dc.date.created2009-03-31T20:01:12Z
dc.date.issued2008
dc.identifier.citationChan, Dick and Chen, Meifania and Ooi, Esther and Watts, Gerald. 2008. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?. International Journal of Clinical Practice. 62 (5): pp. 799-809.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/22580
dc.identifier.doi10.1111/j.1742-1241.2007.01678.x
dc.description.abstract

Background: Hypertriglyceridaemia, commonly found in subjects with obesity and type 2 diabetes mellitus, is associated with increased risk of coronary heart disease (CHD). Apolipoprotein C-III (apoC-III) plays an important role in regulating the metabolism of triglyceride-rich lipoproteins (TRLs) and may provide a new approach to assessing hypertriglyceridaemia. Aims: We review the role of apoC-III in regulating TRL metabolism and address the potential importance of apoC-III in clinical practice. Discussion: Hypertriglyceridaemia is chiefly a consequence of alterations in the kinetics of TRLs, including overproduction and delayed clearance of very-low density lipoprotein (VLDL). ApoC-III is an inhibitor of lipoprotein lipase and of TRLs remnant uptake by hepatic lipoprotein receptors. Elevated apoC-III, usually resulting from hepatic overproduction of VLDL apoC-III, may cause accumulation of plasma TRLs leading to hypertriglyceridaemia. The results from recent observational studies demonstrate that apoC-III is a strong predictor of risk for CHD, but this chiefly relates to apoC-III in apoB-containing lipoproteins. Lifestyle and pharmacological intervention can correct hypertriglyceridaemia by a mechanism of action that regulates apoC-III transport. Conclusions: Targeting apoC-III metabolism may therefore be an important, new therapeutic approach to managing dyslipidaemia and CHD risk in obesity, insulin resistance and type 2 diabetes mellitus. However, further work is required to establish the practical aspects of measuring apoC-III in routine laboratory service and the precise therapeutic targets for serum total apoC-III and/or apoC-III in apoB-containing lipoproteins. While showing much promise as a potentially useful cardiovascular risk factor, apoC-III is not yet ready for prime time use in clinical practice.

dc.publisherBlackwell Publishing Ltd
dc.titleAn ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
dc.typeJournal Article
dcterms.source.volume62
dcterms.source.number5
dcterms.source.startPage799
dcterms.source.endPage809
dcterms.source.issn17421241
dcterms.source.titleInternational Journal of Clinical Practice
curtin.note

Copyright © 2008 John Wiley & Sons, Inc. All Rights Reserved.

curtin.note

The link to the published version is available at: http://www3.interscience.wiley.com/journal/119418283/abstract

curtin.departmentCentre for Extended Enterprises and Business Intelligence
curtin.accessStatusFulltext not available
curtin.facultyCurtin Business School


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record